These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 322092)

  • 1. [The relation between anti-hypertensive action and plasmatic concentration of pindolol. Preliminary study].
    Weiss Y; Loria Y; Lavene D; Georges D; Safar M; Milliez P
    Nouv Presse Med; 1977 Mar; 6(11):927-30. PubMed ID: 322092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure reactivity in the evaluation of resting blood pressure and mood responses to pindolol and propranolol in hypertensive patients.
    Potempa KM; Fogg LF; Fish AF; Kravitz HM
    Heart Lung; 1993; 22(5):383-91. PubMed ID: 8226001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.
    Waal-Manning HJ; Simpson FO
    N Z Med J; 1974 Aug; 80(522):151-7. PubMed ID: 4608769
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Adv Clin Pharmacol; 1976; 11():1114-8. PubMed ID: 802071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.
    Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Sievert A; Aurell M; Hansson L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S102-4. PubMed ID: 2455104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pindolol as an antihypertensive agent].
    Pinggera WF; Fitscha P; Stummvoll HK; Wolf A; Dorda P
    Fortschr Med; 1977 Feb; 95(5):310-14. PubMed ID: 838451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
    Serro-Azul JB; Wajngarten M; Santomauro A; Braga A; Yazbek Júnior P; Bellotti G; Serro-Azul LG; Pileggi F
    Arq Bras Cardiol; 1989 Dec; 53(6):321-5. PubMed ID: 2700113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct 24-hour haemodynamic monitoring after starting beta-blocker therapy: studies with pindolol in hypertension.
    v d Meiracker A; Man in't Veld AJ; van Eck HR; Wenting GJ; Schalekamp MA
    J Hypertens Suppl; 1984 Dec; 2(3):S581-3. PubMed ID: 6100755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ketanserin and pindolol in hypertension.
    Gordin A; Saraste K; Turanlahti M; Sundberg S
    J Hypertens Suppl; 1986 Apr; 4(1):S61-2. PubMed ID: 2939214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experiences with carteolol in patients with essential hypertension].
    Viehmann P
    Arzneimittelforschung; 1983; 33(2a):322-5. PubMed ID: 6340701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of Viskaldix in patients with primary hypertension].
    Cybulska I; Sznajderman M
    Pol Tyg Lek; 1983 Nov; 38(45):1399-401. PubMed ID: 6374634
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect and tolerability of Viskaldix retard in ambulatory hypertensive patients].
    Kredel L
    Med Welt; 1984 Feb; 35(5):156-9. PubMed ID: 6366438
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the hypotensive effect of Viskaldix].
    Wyrzykowski B; Suchecka-Rachoń K; Krupa-Wojciechowska B
    Przegl Lek; 1985; 42(11):750-4. PubMed ID: 3912842
    [No Abstract]   [Full Text] [Related]  

  • 14. [Influence of some parameters on the blood pressure reduction under treatment: experience from the Hypertension Optimal Treatment Study].
    Mallion JM; Baguet JP; Siché JP; Benkritly A
    Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1049-53. PubMed ID: 9749163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension.
    Chalmers JP; Korner PI; Tiller DJ; Bune AJ; Steiner JD; West MJ; Wing LM; Uther JF
    Med J Aust; 1976 May; 1(18):650-3. PubMed ID: 781495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group.
    Joglekar SJ; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():52-62. PubMed ID: 11233387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
    Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of pindolol and alpha-methyldopa in treatment of mild to moderate hypertension: results of a double-blind evaluative study.
    Beanlands DS; Allard PP; Wilson M; Orbeck KW; Helman AB; Lefebvre R
    Clin Invest Med; 1978; 1(3-4):139-45. PubMed ID: 391453
    [No Abstract]   [Full Text] [Related]  

  • 19. [Blood pressure and renin activity in essential hypertension under pindolol].
    Nussberger J; Vetter W; Furrer J; Beckerhoff R; Würsten D; Schmied U; Siegenthaler W
    Schweiz Med Wochenschr; 1976 Jun; 106(24):831-4. PubMed ID: 996500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical pharmacology of the antihypertensive action of pindolol].
    Safar M; Weiss Y; Georges D; Milliez P
    Coeur Med Interne; 1975; 14(4):477-83. PubMed ID: 1106939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.